May/June 2021

A Slow and Steady… Boom?

Robert L. Avery, MD, and Allen C. Ho, MD

The New Frontier: Gene Therapy for AMD

Clinical trials, although in the earliest phases, are showing exciting results. How might these treatments impact your practice in the future?

Robert L. Avery, MD; Peter A. Campochiaro, MD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; Charles Wykoff, MD, PhD; and Allen C. Ho, MD

Monitoring For Wet AMD in the Fellow Eye

Extended treatment intervals may affect disease detection. Here’s what you can do to catch it early.

Byron Ladd, MD, and Miguel Busquets, MD

How Would You Handle These Tough AMD Cases?

Whether it’s subretinal hyperreflective material, retinal angiomatous proliferation, or polypoidal choroidal vasculopathy, your colleagues have the answers.

Sumit Randhir Singh, MD; Jay Chhablani, MD; Julia Farah Agi, MD; Michel Eid Farah, MD, PhD; Aneesha Kalur, BA; Rishi P. Singh, MD; and Amani Fawzi, MD

Anti-VEGF Therapy: Past, Present, and Future

These agents have fundamentally changed how we care for our patients. Here’s my personal perspective on—and role in—the development of the story.

Robert L. Avery, MD

The Utility of CAM OCT Criteria for AMD Clinical Trials

Can this classification system help researchers consistently assess atrophy in patients undergoing treatment for AMD? New data suggest that it can.

Glenn J. Jaffe, MD

Therapies on the Horizon for Nonexudative AMD

New targets in the complement pathway are showing promise for reducing geographic atrophy progression.

Charles C. Wykoff, MD, PhD; Erin Henry, PhD; SriniVas R. Sadda, MD; Jeffrey S. Heier, MD; Nadia K. Waheed, MD, MPH; and Pravin U. Dugel, MD

Improving Membrane Visualization in the OR

Adjusting parameters on 3D heads-up display systems can enhance the effect of dyes.

Alline G.R. Melo, MD; Thais F. Conti, MD; and Rishi P. Singh, MD

Classical Presentation, Unlikely Geographical Location

This case of juvenile neuronal ceroid lipofuscinosis may be the first reported in Ecuador.

Juan Pablo Murillo-Zambrano, MD; María F. Osorio, MD; Jorge Murillo Acuña, MD; Simone Finzi, MD, PhD; and Marc Safran, MD

Glaucoma in the Retina Practice: Part 2

Understanding the mechanism of IOP elevation after vitreoretinal surgery helps guide the best management approach.

Steve Charles, MD, FACS, FICS, and Adam Pflugrath, MD

Intraarterial Chemotherapy: The Latest Tidal Wave

Here’s a look at the evolution of this therapeutic option for the management of retinoblastoma.

Zaynab Sajjadi, BA; Antonio Yaghy, MD; Fairooz P. Manjandavida, MD; and Carol L. Shields, MD

Cytomegalovirus Retinitis Without Immunocompromise

What could have predisposed this immunocompetent patient to this complication with extensive retinal ischemia?

Michael C. Izzo, MD; Mariam Mathai, MD; and Brian K. Do, MD

Tracking a Case of Valsalva Retinopathy

A new predictive tool could help clinicians catch complications after laser membranotomy.

Kushal Delhiwala, MBBS, MS, FMRF, FICO

5Q with Netan Choudhry, MD, FRCSC

Netan Choudhry, MD, FRCSC